axsomelogo-468x57.jpg
Axsome Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update
November 09, 2018 07:00 ET | Axsome Therapeutics, Inc.
Final Phase 3 results of AXS-05 in treatment resistant depression now anticipated in 1Q 2019 Final Phase 2 results of AXS-05 in major depressive disorder anticipated around year-end 2018 Phase 2/3...
axsomelogo-468x57.jpg
Axsome Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update
May 08, 2018 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
axsomelogo-468x57.jpg
Axsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
March 07, 2018 07:00 ET | Axsome Therapeutics, Inc.
Interim analyses of STRIDE-1 and ADVANCE-1 trials of AXS-05 anticipated in 2018 Company to host conference call today at 8:00 AM Eastern NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Axsome...
axsomelogo-468x57.jpg
Axsome Therapeutics to Present at 2018 BIO CEO & Investor Conference
February 05, 2018 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial
January 09, 2018 07:00 ET | Axsome Therapeutics, Inc.
COAST-1 is a Phase 3 trial of AXS-02 in knee osteoarthritis associated with bone marrow lesions CREATE-1 is a Phase 3 trial of AXS-02 in complex regional pain syndrome Significant reduction in bone...
axsomelogo-468x57.jpg
Axsome Therapeutics to Present at Biotech Showcase 2018
December 19, 2017 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
axsomelogo-468x57.jpg
Axsome Therapeutics Reports Third Quarter 2017 Financial Results
November 08, 2017 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
axsomelogo-468x57.jpg
Axsome Therapeutics to Present at Upcoming Investor Conferences
September 18, 2017 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
axsomelogo-468x57.jpg
Axsome Announces CREATE-1 Interim Analysis Expected Year-End 2017
September 07, 2017 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
axsomelogo-468x57.jpg
Axsome Therapeutics Reports Second Quarter 2017 Financial Results
August 09, 2017 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...